|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
ABI1, a member of WAVE complex and actin cytoskeleton regulator and adaptor protein, acts as tumor suppressor in prostate cancer but the role of ABI1 in EMT is not clear.
|
31530281 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
We previously demonstrated that Abelson interactor 1 (Abi-1), a negative regulator of Abelson kinase 1, functions as a tumor suppressor.
|
30213875 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Moreover, high ABI1 expression was significantly correlated with tumor size (P=0.041), tumor number (P<0.001), tumor encapsulation (P<0.001) and BCLC stage (P=0.010).
|
28339046 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In conclusion, our findings suggest that Abi1 acts as a tumor-promoting gene in EOC progression, which may lead to unfavorable prognosis.
|
26193797 |
2015 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In 56 primary human colorectal carcinoma samples, we found overexpression of Abi1 in 39% at the invasive edge of the tumour, associated with an infiltrative phenotype and high-grade tumour cell budding (p = 0.001).
|
24913355 |
2014 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Abi1 expression in carcinoma was independent of microsatellite stability of the tumor.
|
22808230 |
2012 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
ABI1 expression in 103 patients was strongly correlated with tumor differentiation, clinical stage, and lymph node status (P < 0.01).
|
19554484 |
2010 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
TAT-p + p-8 peptide could disrupt ABI1-EPS8 interaction and suppress the invasion and metastasis of ovarian cancer cells in vivo.
|
31488087 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, in vitro studies indicated that overexpression of ABI1 induced an increase in cell proliferation, migration and invasion of HCC cells, whereas knockdown of ABI1 did the opposite.
|
28339046 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
PosttranslationalModification
|
phenotype |
BEFREE |
Importantly, treatment with STI571 did abolish Abi1 Y435-phosphorylation, suppressed the matrix dissolution, decreased fibronectin attachment, and suppressed cell invasion through reconstituted extracellular matrix.
|
24913355 |
2014 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Previous in vitro work suggested that Abi1 is a regulator of breast cancer proliferation, migration, and invasion.
|
21046228 |
2011 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Due to its role in cell mobility, we hypothesized that ABI-1 has a role in invasion and metastasis.
|
17951403 |
2007 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Thus, C. trachomatis activates Rac and promotes its interaction with WAVE2 and Abi-1 to activate the Arp2/3 complex resulting in the induction of actin cytoskeletal rearrangements that are required for invasion.
|
17501982 |
2007 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
TAT-p + p-8 peptide could disrupt ABI1-EPS8 interaction and suppress the invasion and metastasis of ovarian cancer cells in vivo.
|
31488087 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Low ABI1 expression is associated with biochemical recurrence, metastasis and death (p = 0.038).
|
31530281 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, our aim was to investigate the expression of Abi1 in colonic mucosa with and without inflammation, colonic polyps, colorectal carcinomas (CRC) and metastases as well as in CRC cell lines with respect to BRAF/KRAS mutation status and to find out whether introduction of KRAS mutation or stimulation with TNFalpha enhances Abi1 protein expression in CRC cells.
|
22808230 |
2012 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our study implicates that the integrity of SOS1/EPS8/ABI1 tri-complex is a determinant of ovarian cancer metastasis.
|
21118970 |
2010 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Due to its role in cell mobility, we hypothesized that ABI-1 has a role in invasion and metastasis.
|
17951403 |
2007 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
To investigate the molecular mechanism by which loss of ABI1 contributes to tumor progression, we disrupted the ABI1 gene in the benign prostate epithelial RWPE-1 cell line and determined its phenotype.
|
31530281 |
2019 |